Impact News +++ Planet Labs Stock Pauses Monday While Space Stocks Remain Volatile: What′s Going On? (Benzinga) +++ PLANET LABS Aktie +3,65%

MYRIAD GENETICS Aktie

>MYRIAD GENETICS Aktienkurs

3.803 EUR (TradegateBSX)

Ask: 3.864 EUR / 1293 Stück

Bid: 3.742 EUR / 1336 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

Aktie über LYNX handeln

Intraday

1 Jahr

>MYRIAD GENETICS Performance

1 Woche: +1,9%

1 Monat: +2,8%

3 Monate: -15,1%

6 Monate: -38,2%

1 Jahr: -14,0%

laufendes Jahr: -28,9%

>MYRIAD GENETICS Aktie

Name:

MYRIAD GENETICS DL-,01

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US62855J1043 / 897518

Symbol/ Ticker:

MYD (Frankfurt) / MYGN (NASDAQ)

Kürzel:

FRA:MYD, ETR:MYD, MYD:GR, NASDAQ:MYGN

Index:

Webseite:

https://myriad.com/

Profil:

Myriad Genetics Inc. is a biotechnology company specializing in the development and commercialization of genetic tests that assess risk for cancer and other hereditary conditions. The company is renowned for its pioneering efforts in molecular diagno..
>Volltext..

Marktkapitalisierung:

360.67 Mio. EUR

Unternehmenswert:

436.64 Mio. EUR

Umsatz:

719.48 Mio. EUR

EBITDA:

-11.54 Mio. EUR

Nettogewinn:

-347.07 Mio. EUR

Gewinn je Aktie:

-3.75 EUR

Schulden:

183.56 Mio. EUR

Liquide Mittel:

107.97 Mio. EUR

Operativer Cashflow:

Bargeldquote:

0.96

Umsatzwachstum:

-6.62%

Gewinnwachstum:

-269.28%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

1 Insider kaufte innerhalb der letzten 30 Tage Aktien im Wert von 23.977 Euro.

Suchwörter:

MYRIAD GENETICS

Letzte Datenerhebung:

08.06.26

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 94.45 Mio. St.

Frei handelbar: 93.63%

Leerverk. Aktien: 8.82%

Rückkaufquote: -0.79%

Mitarbeiter: 2700

Umsatz/Mitarb.: 0.27 Mio. EUR

Analysten:

Analystenrating: Neutral

Kursziel: 34.68%

Bewertung:

KGV: -

KGV lG: 76.15

KUV: 0.53

KBV: 1.3

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 66.14%

Gewinnmarge: -48.24%

Operative Marge: -7.73%

Managementeffizenz:

Gesamtkaprendite: -47.61%

Eigenkaprendite: -76.73%

>Peer Group

Gesundheit, Onkologie/ Krebs- Behandlung, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten

>MYRIAD GENETICS Chart & Kurs - NASDAQ

>MYRIAD GENETICS News

02.06.26 - 15:09	Myriad Genetics Names Raj Jampa as New Chief Technology Officer (GlobeNewswire EN)
	Myriad Genetics announces the appointment of Raj Jampa as chief technology officer (CTO)....

28.05.26 - 16:45	Myriad Genetics′ Upcoming Prolaris + AI Test Debut May Lift Its Stock (Zacks)
	MYGN plans to launch its Prolaris + AI Test this month, combining biomarker data and AI pathology to personalize prostate cancer surveillance....

28.05.26 - 16:45	Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh (Zacks)
	Myriad Genetics trades near 0.4x sales as investors weigh cheap valuation against 2026 launch execution and uneven segment performance....

27.05.26 - 15:09	Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting (GlobeNewswire EN)
	Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting...

26.05.26 - 22:09	Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI) (GlobeNewswire EN)
	Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence...

15.05.26 - 17:03	Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life (GlobeNewswire EN)
	Myriad Genetics joins forces with Nobody Wants This actress Jackie Tohn...

15.05.26 - 02:02	Insiderhandel: Aufsichtsrat kauft Aktien von Myriad Genetics im Wert von 27638 USD (Insiderkauf)
	Bisaro, Paul - Aufsichtsrat - Tag der Transaktion: 2026-05-14...

07.05.26 - 22:09	Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences (GlobeNewswire EN)
	Myriad Genetics will participate in The BofA Securities 2026 Health Care Conference and Goldman Sachs 47th Annual Global Healthcare Conference....

06.05.26 - 20:24	Myriad Genetics in record sell-off after Q1 miss (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

06.05.26 - 04:00	Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
	Myriad (MYGN) delivered earnings and revenue surprises of -56.52% and -1.09%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?...

06.05.26 - 00:06	Myriad Genetics: Gemischte Ergebnisse für Q1 2026 – Prognosen verfehlt, aber Wachstum in Kernsegmenten (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

30.04.26 - 15:09	Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan (GlobeNewswire EN)
	The latest GeneSight® Mental Health Monitor from Myriad Genetics reveals that Americans feel mental health treatment isn't designed with them in mind....

28.04.26 - 22:09	Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026 (GlobeNewswire EN)
	Myriad Genetics will hold its first quarter 2026 earnings conference call at 4:30 pm ET on Tuesday, May 5, 2026. Webcast at investor.myriad.com....

28.04.26 - 17:31	Analysts Estimate Myriad Genetics (MYGN) to Report a Decline in Earnings: What to Look Out for (Zacks)
	Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

16.04.26 - 15:18	Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026 (GlobeNewswire EN)
	Myriad Genetics will share six abstracts, including two podium presentations, at the American Association for Cancer Research (AACR) Annual Meeting....

14.04.26 - 15:18

Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan (GlobeNewswire EN)

SALT LAKE CITY, April 14, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved the use of the MyChoice® Test for prostate cancer patients as a companion diagnostic for Lynparza® (olaparib). With this approval, clinicians can now order the MyChoice Test to determine homologous recombination deficiency (HRD) status for patients with ovarian cancer, and BRCA1/2 status for breast and prostate cancers....

09.04.26 - 15:18	Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting (GlobeNewswire EN)
	Myriad will share new data at the Society of Gynecologic Oncology (SGO) Annual Meeting April 10-13, including two oral presentations and two posters....

19.03.26 - 16:30	Why Myriad Genetics (MYGN) is a Top Growth Stock for the Long-Term (Zacks)
	The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage....

18.03.26 - 16:30	Why Myriad Genetics (MYGN) is a Top Momentum Stock for the Long-Term (Zacks)
	Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service....

17.03.26 - 21:09	Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer (GlobeNewswire EN)
	Myriad announces FDA approval for the MyChoice CDx Test as the Companion Diagnostic for Zejula, a PARP inhibitor from GSK, for patients with ovarian cancer...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Noli me tangere! - Rühr mich nicht an! - Neues Testament: Evangelium nach Johannes

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram